Advisors Asset Management Inc. Sells 13,701 Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC)

Advisors Asset Management Inc. reduced its position in Marsh & McLennan Companies, Inc. (NYSE:MMC - Free Report) by 28.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,006 shares of the financial services provider's stock after selling 13,701 shares during the quarter. Advisors Asset Management Inc.'s holdings in Marsh & McLennan Companies were worth $7,809,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Carmichael Hill & Associates Inc. raised its stake in Marsh & McLennan Companies by 85.7% during the third quarter. Carmichael Hill & Associates Inc. now owns 130 shares of the financial services provider's stock worth $29,000 after purchasing an additional 60 shares during the period. Catalyst Capital Advisors LLC purchased a new position in Marsh & McLennan Companies in the third quarter worth approximately $31,000. Crewe Advisors LLC lifted its position in shares of Marsh & McLennan Companies by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 160 shares of the financial services provider's stock worth $34,000 after purchasing an additional 80 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in Marsh & McLennan Companies in the third quarter valued at $41,000. Finally, Ridgewood Investments LLC acquired a new position in shares of Marsh & McLennan Companies during the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 87.99% of the company's stock.

Marsh & McLennan Companies Price Performance

Marsh & McLennan Companies stock traded up $0.12 on Thursday, reaching $222.08. The company's stock had a trading volume of 373,128 shares, compared to its average volume of 1,682,329. Marsh & McLennan Companies, Inc. has a twelve month low of $184.28 and a twelve month high of $232.32. The business's fifty day moving average price is $223.81 and its 200 day moving average price is $218.49. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.14 and a current ratio of 1.14. The company has a market cap of $109.07 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 3.29 and a beta of 0.94.

Marsh & McLennan Companies (NYSE:MMC - Get Free Report) last released its earnings results on Thursday, October 17th. The financial services provider reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.02. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.71 billion. Marsh & McLennan Companies had a net margin of 16.82% and a return on equity of 32.65%. Marsh & McLennan Companies's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.57 earnings per share. Equities analysts expect that Marsh & McLennan Companies, Inc. will post 8.69 earnings per share for the current fiscal year.

Marsh & McLennan Companies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Friday, October 4th were given a $0.815 dividend. The ex-dividend date was Friday, October 4th. This represents a $3.26 dividend on an annualized basis and a dividend yield of 1.47%. Marsh & McLennan Companies's dividend payout ratio (DPR) is presently 40.15%.

Insider Transactions at Marsh & McLennan Companies

In other Marsh & McLennan Companies news, Director Oscar Fanjul sold 2,500 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $221.55, for a total transaction of $553,875.00. Following the completion of the transaction, the director now owns 48,549 shares of the company's stock, valued at approximately $10,756,030.95. This trade represents a 4.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

MMC has been the subject of several research analyst reports. Barclays increased their price objective on Marsh & McLennan Companies from $236.00 to $246.00 and gave the company an "equal weight" rating in a report on Thursday. BMO Capital Markets boosted their price target on shares of Marsh & McLennan Companies from $217.00 to $228.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Wells Fargo & Company cut their price target on shares of Marsh & McLennan Companies from $212.00 to $211.00 and set an "equal weight" rating for the company in a report on Thursday, October 10th. UBS Group boosted their price objective on shares of Marsh & McLennan Companies from $255.00 to $259.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. Finally, Keefe, Bruyette & Woods boosted their price objective on shares of Marsh & McLennan Companies from $209.00 to $212.00 and gave the company an "underperform" rating in a research report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $226.00.

Marsh & McLennan Companies Profile

Marsh & McLennan Companies, Inc, a professional services company, provides advice and solutions to clients in the areas of risk, strategy, and people worldwide. It operates through Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment offers risk management services, such as risk advice, risk transfer, and risk control and mitigation solutions, as well as insurance and reinsurance broking, strategic advisory services, and analytics solutions, and insurance program management services.